Suppr超能文献

美国心脏病学会基金会/美国心脏协会心血管技术质量指标制定方法学:美国心脏病学会基金会/美国心脏协会绩效指标工作组的报告。

ACCF/AHA methodology for the development of quality measures for cardiovascular technology: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures.

出版信息

Circulation. 2011 Sep 27;124(13):1483-502. doi: 10.1161/CIR.0b013e31822935fc. Epub 2011 Aug 29.

Abstract

Consistent with the growing national focus on healthcare quality, the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have taken a leadership role over the past decade in developing measures of the quality of cardiovascular care by convening a joint ACCF/AHA Task Force on Performance Measures. The Task Force is charged with identifying the clinical topics appropriate for the development of performance measures and with assembling writing committees composed of clinical and methodological experts in collaboration with appropriate subspecialty societies. The Task Force has also created methodology documents that offer guidance in the development of process, outcome, composite, and efficiency measures. Cardiovascular performance measures using existing ACCF/AHA methodology are based on Class I or Class III guidelines recommendations, usually with Level A evidence. These performance measures, based on evidence-based ACCF/AHA guidelines, remain the most rigorous quality measures for both internal quality improvement and public reporting. However, many of the tools for diagnosis and treatment of cardiovascular disease involve advanced technologies, such as cardiac imaging, for which there are often no underlying guideline documents. Because these technologies affect the quality of cardiovascular care and also have the potential to contribute to cardiovascular health expenditures, there is a need for more critical assessment of the use of technology, including the development of quality and performance measures in areas in which guideline recommendations are absent. The evaluation of quality in the use of cardiovascular technologies requires consideration of multiple parameters that differ from other healthcare processes. The present document describes methodology for development of 2 new classes of quality measures in these situations, appropriate use measures and structure/safety measures. Appropriate use measures are based on specific indications, processes, or parameters of care for which high level of evidence data and Class I or Class III guideline recommendations may be lacking but are addressed in ACCF appropriate use criteria documents. Structure/safety measures represent measures developed to address structural aspects of the use of healthcare technology (e.g., laboratory accreditation, personnel training, and credentialing) or quality issues related to patient safety when there are neither guidelines recommendations nor appropriate use criteria. Although the strength of evidence for appropriate use measures and structure/safety measures may not be as strong as that for formal performance measures, they are quality measures that are otherwise rigorously developed, reviewed, tested, and approved in the same manner as ACCF/AHA performance measures. The ultimate goal of the present document is to provide direction in defining and measuring the appropriate use-avoiding not only underuse but also overuse and misuse-and proper application of cardiovascular technology and to describe how such appropriate use measures and structure/safety measures might be developed for the purposes of quality improvement and public reporting. It is anticipated that this effort will help focus the national dialogue on the use of cardiovascular technology and away from the current concerns about volume and cost alone to a more holistic emphasis on value.

摘要

与日益关注医疗保健质量的国家趋势保持一致,美国心脏病学会基金会(ACCF)和美国心脏协会(AHA)在过去十年中发挥了领导作用,通过召集一个 ACCF/AHA 联合工作组来制定心血管护理质量的衡量标准。该工作组的任务是确定适合制定绩效措施的临床主题,并与适当的专业协会合作,组建由临床和方法学专家组成的写作委员会。该工作组还创建了方法学文件,为制定流程、结果、综合和效率措施提供指导。使用现有 ACCF/AHA 方法的心血管绩效措施基于 I 类或 III 类指南建议,通常具有 A 级证据。这些基于循证 ACCF/AHA 指南的绩效措施仍然是内部质量改进和公共报告的最严格的质量措施。然而,许多心血管疾病的诊断和治疗工具都涉及到心脏成像等先进技术,而这些技术通常没有基础指南文件。由于这些技术会影响心血管护理的质量,并且有可能对心血管健康支出产生影响,因此需要对技术的使用进行更严格的评估,包括在没有指南建议的情况下制定质量和绩效措施。评估心血管技术使用的质量需要考虑与其他医疗保健流程不同的多个参数。本文件描述了在这些情况下制定两类新质量措施(适当使用措施和结构/安全措施)的方法。适当使用措施基于缺乏高水平证据数据和 I 类或 III 类指南建议但在 ACCF 适当使用标准文件中有所涉及的特定适应证、流程或护理参数。结构/安全措施是为解决医疗技术使用的结构方面(例如,实验室认证、人员培训和认证)或当既没有指南建议也没有适当使用标准时与患者安全相关的质量问题而制定的措施。虽然适当使用措施和结构/安全措施的证据强度可能不如正式绩效措施强,但它们是经过严格制定、审查、测试和批准的质量措施,与 ACCF/AHA 绩效措施的方式相同。本文件的最终目标是提供定义和衡量适当使用的指导,不仅要避免使用不足,还要避免过度使用和误用,并适当应用心血管技术,并描述如何为质量改进和公共报告目的制定适当使用措施和结构/安全措施。预计这一努力将有助于将全国对话的重点从当前对数量和成本的关注转移到更全面地关注价值上。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验